dc.contributor.author |
Tutuncu M. |
dc.contributor.author |
Tang J. |
dc.contributor.author |
Zeid N.A. |
dc.contributor.author |
Kale N. |
dc.contributor.author |
Crusan D.J. |
dc.contributor.author |
Atkinson E.J. |
dc.contributor.author |
Siva A. |
dc.contributor.author |
Pittock S.J. |
dc.contributor.author |
Pirko I. |
dc.contributor.author |
Keegan B.M. |
dc.contributor.author |
Lucchinetti C.F. |
dc.contributor.author |
Noseworthy J.H. |
dc.contributor.author |
Rodriguez M. |
dc.contributor.author |
Weinshenker B.G. |
dc.contributor.author |
Kantarci O.H. |
dc.contributor.editor |
|
dc.date |
2013 |
dc.date.accessioned |
2017-10-05T15:40:03Z |
dc.date.available |
2017-10-05T15:40:03Z |
dc.date.issued |
2013 |
dc.identifier |
10.1177/1352458512451510 |
dc.identifier.isbn |
|
dc.identifier.issn |
13524585 |
dc.identifier.uri |
http://hdl.handle.net/10938/17220 |
dc.description.abstract |
Background: It is unclear if all patients with relapsing-remitting multiple sclerosis (RRMS) ultimately develop progressive MS. Onset of progressive disease course seems to be age- rather than disease duration-dependent. Some forms of progressive MS (e.g. primary progressive MS (PPMS)) are uncommon in population-based studies. Ascertainment of patients with PPMS from clinic-based populations can facilitate a powerful comparison of age at progression onset between secondary progressive MS (SPMS) and PPMS but may introduce unclear biases. Objective: Our aim is to confirm that onset of progressive disease course is more relevant to the patient's age than the presence or duration of a pre-progression relapsing disease course in MS. Methods: We studied a population-based MS cohort (n=210, RRMS n=109, progressive MS n=101) and a clinic-based progressive MS cohort (n=754). Progressive course was classified as primary (PPMS; n=322), single attack (SAPMS; n=112) and secondary progressive (SPMS; n=421). We studied demographics (chi2 or t-test), age-of-progression- onset (t-test) and time to Expanded Disability Status Scale of 6 (EDSS6) (Kaplan-Meier analyses). Results: Sex ratio (p=0.58), age at progression onset (p=0.37) and time to EDSS6 (p=0.16) did not differ between the cohorts. Progression had developed before age 75 in 99percent of patients with known progressive disease course; 38percent with RRMS did not develop progression by age 75. Age at progression onset did not differ between SPMS (44.9±9.6), SAPMS (45.5±9.6) and PPMS (45.7±10.8). In either cohort, only 2percent of patients had reached EDSS6 before onset of progression. Conclusions: Patients with RRMS do not inevitably develop a progressive disease course. Onset of progression is more dependent on age than the presence or duration of a pre-progression symptomatic disease course. Moderate disability is sustained predominantly after the onset of a progressive disease course in MS. © The Author(s) 2012. |
dc.format.extent |
|
dc.format.extent |
Pages: (188-198) |
dc.language |
English |
dc.publisher |
LONDON |
dc.relation.ispartof |
Publication Name: Multiple Sclerosis; Publication Year: 2013; Volume: 19; no. 2; Pages: (188-198); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis |
dc.type |
Article |
dc.contributor.affiliation |
Tutuncu, M., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Tang, J., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Zeid, N.A., Department of Neurology, American University of Beirut Medical Center, Lebanon, Department of Neurology, Mayo Clinic College of Medicine, United States |
dc.contributor.affiliation |
Kale, N., Department of Neurology, Bakirkoy State Hospital, Istanbul, Turkey, Department of Neurology, Mayo Clinic College of Medicine, United States |
dc.contributor.affiliation |
Crusan, D.J., Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, United States |
dc.contributor.affiliation |
Atkinson, E.J., Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, United States |
dc.contributor.affiliation |
Siva, A., Department of Neurology, Cerrahpasa School of Medicine, Istanbul University, Turkey |
dc.contributor.affiliation |
Pittock, S.J., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Pirko, I., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Keegan, B.M., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Lucchinetti, C.F., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Noseworthy, J.H., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Rodriguez, M., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Weinshenker, B.G., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.affiliation |
Kantarci, O.H., Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States |
dc.contributor.authorAddress |
Kantarci, O.H.; Mayo Clinic Center for Multiple Sclerosis and CNS Demyelinating Diseases, Department of Neurology, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, United States; email: kantarci.orhun@mayo.edu |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Neurology; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
Neurology |
dc.contributor.authorEmail |
kantarci.orhun@mayo.edu |
dc.contributor.authorFaculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Tutuncu, M |
dc.contributor.authorInitials |
Tang, J |
dc.contributor.authorInitials |
Abou Zeid, N |
dc.contributor.authorInitials |
Kale, N |
dc.contributor.authorInitials |
Crusan, DJ |
dc.contributor.authorInitials |
Atkinson, EJ |
dc.contributor.authorInitials |
Siva, A |
dc.contributor.authorInitials |
Pittock, SJ |
dc.contributor.authorInitials |
Pirko, I |
dc.contributor.authorInitials |
Keegan, BM |
dc.contributor.authorInitials |
Lucchinetti, CF |
dc.contributor.authorInitials |
Noseworthy, JH |
dc.contributor.authorInitials |
Rodriguez, M |
dc.contributor.authorInitials |
Weinshenker, BG |
dc.contributor.authorInitials |
Kantarci, OH |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Kantarci, OH (reprint author), Mayo Clin and Mayo Fdn, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Bejaoui K, 2010, NEUROLOGY, V74, P900, DOI 10.1212-WNL.0b013e3181d55ee9; Bennetto L, 2011, MULT SCLER J, V17, P1218, DOI 10.1177-1352458511407368; Bramow S, 2010, BRAIN, V133, P2983, DOI 10.1093-brain-awq250; Confavreux C, 2006, BRAIN, V129, P606, DOI 10.1093-brain-awl007; Confavreux C, 2006, CLIN NEUROL NEUROSUR, V108, P327, DOI 10.1016-j.clineuro.2005.11.018; CONFAVREUX C, 1980, BRAIN, V103, P281, DOI 10.1093-brain-103.2.281; Confavreux C, 2006, BRAIN, V129, P595, DOI 10.1093-brain-awh714; Gholipour T, 2011, NEUROLOGY, V76, P1996, DOI 10.1212-WNL.0b013e31821e559d; Hasan KM, BRAIN STRUCT FUNCT, V214, P361; Kantarci O, 1998, NEUROLOGY, V51, P765; Kantarci OH, 2004, NEUROLOGY, V62, P811; Kantarci OH, 2005, NEUROL CLIN, V23, P17, DOI 10.1016-j.ncl.2004.10.002; Kappos L, 2004, NEUROLOGY, V63, P1779; Koch M, 2007, J NEUROL SCI, V255, P35, DOI 10.1016-j.jns.2007.01.067; Kremenchutzky M, 2006, BRAIN, V129, P584, DOI 10.1093-brain-awh721; Kurtzke IF, 1983, NEUROLOGY, V33, P1444; Lebrun C, 2008, J NEUROL NEUROSUR PS, V79, P195, DOI 10.1136-jnnp.2006.108274; Lublin FD, 1996, NEUROLOGY, V46, P907; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002-ana.1032; McDonnell GV, 2003, MULT SCLER J, V9, P204, DOI 10.1191-1352458503ms890cr; Okuda DT, 2009, NEUROLOGY, V72, P800, DOI 10.1212-01.wnl.0000335764.14513.1a; Pittock SJ, 2004, NEUROLOGY, V62, P51; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002-ana.22366; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002-ana.206703; Renoux C, 2007, NEW ENGL J MED, V356, P2603, DOI 10.1056-NEJMoa067597; RODRIGUEZ M, 1994, NEUROLOGY, V44, P28; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093-brain-116.1.117; Scalfari A, NEUROLOGY, V77, P1246; Siva A, 2009, MULT SCLER, V15, P918, DOI 10.1177-1352458509106214; THOMPSON AJ, 1991, ANN NEUROL, V29, P53, DOI 10.1002-ana.410290111; Thompson AJ, 1997, BRAIN, V120, P1085, DOI 10.1093-brain-120.6.1085; Tremlett H, 2009, NEUROLOGY, V73, P1616, DOI 10.1212-WNL.0b013e3181c1e44f; Tremlett H, 2009, J NEUROL, V256, P374, DOI 10.1007-s00415-009-0039-7; Trojano M, 2002, ANN NEUROL, V51, P475, DOI 10.1002-ana.10147; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093-brain-112.1.133; Westlye LT, CEREB CORTEX, V20, P2055; Wolinsky JS, 2003, J NEUROL SCI, V206, P145, DOI 10.1016-S0022-510X(02)00346-5; Yeh EA, 2009, NAT REV NEUROL, V5, P621, DOI 10.1038-nrneurol.2009.158 |
dc.description.citedCount |
8 |
dc.description.citedTotWOSCount |
10 |
dc.description.citedWOSCount |
10 |
dc.format.extentCount |
11 |
dc.identifier.articleNo |
|
dc.identifier.coden |
MUSCF |
dc.identifier.pubmedID |
22736750 |
dc.identifier.scopusID |
84873694378 |
dc.identifier.url |
|
dc.publisher.address |
1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Mult. Scler. J. |
dc.relation.ispartOfIssue |
2 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Multiple Sclerosis |
dc.relation.ispartofPubTitleAbbr |
Mult. Scler. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
19 |
dc.source.ID |
WOS:000315607100011 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
disability |
dc.subject.otherAuthKeyword |
EDSS |
dc.subject.otherAuthKeyword |
Multiple sclerosis |
dc.subject.otherAuthKeyword |
outcome measurement |
dc.subject.otherAuthKeyword |
progressive |
dc.subject.otherAuthKeyword |
relapsing remitting |
dc.subject.otherChemCAS |
|
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
aged |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
disease classification |
dc.subject.otherIndex |
disease course |
dc.subject.otherIndex |
disease duration |
dc.subject.otherIndex |
Expanded Disability Status Scale |
dc.subject.otherIndex |
female |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
major clinical study |
dc.subject.otherIndex |
male |
dc.subject.otherIndex |
multiple sclerosis |
dc.subject.otherIndex |
onset age |
dc.subject.otherIndex |
outcome assessment |
dc.subject.otherIndex |
patient referral |
dc.subject.otherIndex |
sex ratio |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Age of Onset |
dc.subject.otherIndex |
Aged |
dc.subject.otherIndex |
Aging |
dc.subject.otherIndex |
Brain |
dc.subject.otherIndex |
Brain Stem |
dc.subject.otherIndex |
Data Interpretation, Statistical |
dc.subject.otherIndex |
Disease Progression |
dc.subject.otherIndex |
Female |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Kaplan-Meier Estimate |
dc.subject.otherIndex |
Longitudinal Studies |
dc.subject.otherIndex |
Male |
dc.subject.otherIndex |
Middle Aged |
dc.subject.otherIndex |
Multiple Sclerosis |
dc.subject.otherIndex |
Multiple Sclerosis, Chronic Progressive |
dc.subject.otherIndex |
Multiple Sclerosis, Relapsing-Remitting |
dc.subject.otherIndex |
Population |
dc.subject.otherIndex |
Sex Ratio |
dc.subject.otherIndex |
Spinal Cord |
dc.subject.otherIndex |
Treatment Outcome |
dc.subject.otherKeywordPlus |
NATURAL-HISTORY |
dc.subject.otherKeywordPlus |
FOLLOW-UP |
dc.subject.otherKeywordPlus |
DIAGNOSTIC-CRITERIA |
dc.subject.otherKeywordPlus |
DISABILITY |
dc.subject.otherKeywordPlus |
MS |
dc.subject.otherKeywordPlus |
DISEASE |
dc.subject.otherKeywordPlus |
IMPAIRMENT |
dc.subject.otherKeywordPlus |
RELAPSE |
dc.subject.otherKeywordPlus |
COHORT |
dc.subject.otherKeywordPlus |
RISK |
dc.subject.otherWOS |
Clinical Neurology |